North America Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory), And By Country - Forecasts From 2022 To 2027

The North American flu diagnostic and treatment market is projected to grow at a CAGR of 13.66% throughout the forecast. The market was valued at US$13,844.604 million in 2020 and is expected to reach a value of US$33,930.568 million by 2027. The growing incidence of influenza in countries like the U.S., Canada, and Mexico is significantly bolstering the demand for flu diagnostic and treatment solutions in the North American region. The rising number of hospitalizations due to influenza-like illness (ILI) is driving the demand for flu treatment solutions, which, in turn, is fueling the market growth of flu diagnostics and treatment across this region. According to the CDC (Center for Disease Control and Prevention), in the U.S. and Canada, influenza, together with pneumonia, is the eighth and seventh leading cause, of death, respectively, while it is the leading cause of death amongst vaccine-preventable diseases in both countries. A smaller number of people in North American countries are taking flu shots, which is also a driving factor behind the growing flu diagnostic and treatment market in North America.

The growing geriatric population in North American countries such as the U.S., Canada, and Mexico is also spurring the demand for flu diagnostic kits and treatment solutions across the region. According to the U.S. Population Reference Bureau Report 2016, the number of Americans aged 65 and above is projected to more than double from 46 million in 2016 to 98 million by 2060. Because elderly people are more susceptible to the flu due to a weakened immune system, the number of hospitalizations will rise as more people reach the age of 65 or older, propelling the market growth of flu diagnostics and treatment in North America over the next five years.  Moreover, the increasing number of people suffering from chronic diseases in these countries will also boost the demand for flu diagnosis and treatment markets across the region. 

The presence of modern healthcare infrastructure is also contributing to the market growth of the flu diagnostic and treatment market in the region. This growth is further supported by the presence of major market players including Abbott, Thermo Fisher Scientific, Pfizer, and Quidel Corporation in the region. Continuous investments in R&D in order to develop new diagnostic kits or any flu treatment medication will also spur the overall market growth of the flu diagnostic and treatment market in North America during the forecast period. For example, in October 2018, Abbott got clearance from the U.S. Food and Drug Administration (FDA) for its next-generation Influenza A & B2 and Strep A2 molecular assays for point-of-care testing.

Growing demand for OTC (over-the-counter) medicines to treat symptoms of flu is also leading to the market growth of the flu diagnostic and treatment market across North American countries. People's increasing willingness to self-medicate for common flu symptoms is driving up demand for OTC drugs.  Moreover, these medicines are cheaper than branded/patented flu medications, which is also a contributing factor to the increasing demand for OTC flu medicines, thereby driving the flu diagnostic and treatment market growth in the region.

The North American flu diagnostic and treatment market has been segmented on the basis of the type of flu, offering, age group, end-user, and country. On the basis of the type of flu, the North American flu diagnostic and treatment market has been classified into type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. The North American flu diagnostic and treatment market has also been segmented by age group as 0-14 years, 15-64 years, and >=65 years. By end-user, the segmentation of the North American flu diagnostic and treatment market has been done on the basis of hospital laboratories, outpatient clinics, and reference laboratories. By country, the market segmentation has been done as the U.S., Canada, and Mexico. The U.S. accounted for the major market share in 2019 and will maintain its dominance till the end of 2025 by growing at the highest CAGR during the forecast period. 

Key Development in the Market

• In May 2022, a UK-based innovator in point-of-care diagnostics, QuantuMDx Group Limited, launched the availability of its new respiratory panel test, the Q-POCTM SARS-CoV-2, Flu A/B & RSV Assay. The Q-POCTM respiratory panel test expands on the Q-POCTM SARS-CoV-2 test, which was introduced formerly in 2021. It gives consumers quickly, point-of-care testing options in a variety of healthcare settings while also significantly increasing the Q-POCTM platform and its multiplex capabilities. With the most recent knowledge of SARS-CoV-2, Flu A/B, and RSV sequences, the Q-POCTM SARS-CoV-2, Flu A/B, and RSV Assay were created to ensure coverage of all known sequences found in publicly accessible databases. 
• In February 2020, to assist consumers to understand and monitor the severity of the flu and cold this winter, IQVIA launched a FluSTAR mobile application. The FluStar app from IQVIA leverages nearly real-time updates gathered from www.FluSTAR.com, which is available from any mobile device and provides current sickness information for every ZIP code in the US. FluSTAR equips medical professionals and patients with the most recent knowledge on the spread of the flu during each influenza. 

COVID-19 Insights:

COVID-19 had a positive impact on the North America Flu and diagnostic market. The use of influenza diagnostic kits to precisely diagnose the source of the infection has surged owing to the similarity in the symptoms of COVID-19, and influenza has many of the same symptoms. Additionally, throughout the epidemic, market demand surged due to the increased government initiatives to stop the seasonal flu from spreading. For instance, according to financials released by GSK, Fluarix/FluLaval sales increased by 35% AER and 37% CER, principally due to strong government recommendations that flu vaccination is prioritized during COVID-19 pandemic conditions and the US's decision to reverse a prior year returns provision.

North America Flu Diagnostic and Treatment Market Scope:

Key Market Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory
• By Country
  • U.S.
  • Canada
  • Mexico